Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients with non-Hodgkin lymphoma. Doses of 1-20 mg daily were given intravenously for up to 43 days. In both patients lymphoma cells were cleared from the blood and bone marrow and splenomegaly resolved. One p...
Autores principales: | Hale, G, Dyer, M, Clark, MR, Phillips, J, Marcus, R, Riechmann, L, Winter, G, Waldmann, H |
---|---|
Formato: | Journal article |
Lenguaje: | English |
Publicado: |
1988
|
Ejemplares similares
-
REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
por: Dyer, M, et al.
Publicado: (1990) -
Specificity of monoclonal antibody Campath-1.
por: Hale, G, et al.
Publicado: (1988) -
CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
por: Hale, G, et al.
Publicado: (1994) -
EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
por: Dyer, M, et al.
Publicado: (1988) -
Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
por: Waldmann, H, et al.
Publicado: (1985)